Holm Elena, Zetterberg Eva, Lövdahl Susanna, Berntorp Erik
Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.
Mediterr J Hematol Infect Dis. 2016 Feb 10;8(1):e2016014. doi: 10.4084/MJHID.2016.014. eCollection 2016.
Patients with mild to moderate bleeding symptoms referred for coagulation investigation sometimes never receive a definitive diagnosis. Bleed assessment tools have been developed and validated to assess the severity of symptoms. Global coagulation assays, e.g., the thrombin generation test (thrombogram) have a potential to identify hemostatic defects that are not detected in specific assays.
One hundred and eighty-five patients referred to our centre because of bleeding symptoms were evaluated using the bleeding assessment tool (BAT) described by Tosetto and colleagues in 2006. Blood samples were investigated for thrombin generation (TG) capacity (Technoclone), in platelet poor (PPP) plasma, and specific clotting factors, i.e., von Willebrand factor, factor VIII and IX, as well as INR, APTT, platelet count, and platelet adhesion.
Of the 185 patients, five women were diagnosed with mild von Willebrand disease and one male with mild hemophilia A. The remaining 179 subjects (76% females and 24% males with average ages of 33 and 28 years, respectively) were evaluated further. In the total cohort and among women, peak TG, and lag time correlated with bleeding score (p=0.01 and p=0.04, respectively with correlation coefficients). No such correlations were found among males.
Although our study showed some correlation between TG and bleeding score, results are generally consistent with a previous report which failed to demonstrate the value of TG measurement in a similar setting. In conclusion, the complexity of the mechanisms underlying clinical bleeding complicates the ability to use TG tests as reliable predictors of bleeding. Mild congenital bleeding disorders, especially VWD, should be specifically screened for in patients with mild/moderate symptoms.
因凝血功能检查而转诊的轻至中度出血症状患者有时始终无法得到明确诊断。已开发并验证了出血评估工具,用于评估症状的严重程度。全球凝血检测,例如凝血酶生成试验(血栓图),有可能识别出在特定检测中未被检测到的止血缺陷。
使用托塞托及其同事在2006年描述的出血评估工具(BAT),对因出血症状转诊至我们中心的185例患者进行评估。检测无血小板血浆(PPP)中凝血酶生成(TG)能力(Technoclone)以及特定凝血因子,即血管性血友病因子、凝血因子VIII和IX,同时检测国际标准化比值(INR)、活化部分凝血活酶时间(APTT)、血小板计数和血小板黏附。
在185例患者中,5名女性被诊断为轻度血管性血友病,1名男性被诊断为轻度甲型血友病。其余179名受试者(女性占76%,男性占24%,平均年龄分别为33岁和28岁)进一步接受评估。在整个队列以及女性中,TG峰值和延迟时间与出血评分相关(相关系数分别为p=0.01和p=0.04)。在男性中未发现此类相关性。
尽管我们的研究显示TG与出血评分之间存在一定相关性,但结果总体上与之前一份未能证明TG检测在类似情况下价值的报告一致。总之,临床出血潜在机制的复杂性使得将TG检测用作出血可靠预测指标的能力变得复杂。对于有轻/中度症状的患者,应特别筛查轻度先天性出血性疾病尤其是血管性血友病。